These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34320542)

  • 1. Hyperthermic intraperitoneal chemotherapy for treating ovarian cancer.
    Gajarawala S; Pelkowski J; Dorian R; Stanton A; Dinh T
    JAAPA; 2021 Aug; 34(8):50-53. PubMed ID: 34320542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
    Lim PQ; Han IH; Seow KM; Chen KH
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
    Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
    Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    Kim SI; Kim JW
    ESMO Open; 2021 Jun; 6(3):100149. PubMed ID: 33984680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translational and pharmacological principles of hyperthermic intraperitoneal chemotherapy for ovarian cancer.
    Vos LMC; Aronson SL; van Driel WJ; Huitema ADR; Schagen van Leeuwen JH; Lok CAR; Sonke GS
    Best Pract Res Clin Obstet Gynaecol; 2022 Jan; 78():86-102. PubMed ID: 34565676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer.
    Schwameis R; Chiva L; Harter P
    Int J Gynecol Cancer; 2022 Apr; 32(4):578. PubMed ID: 35121632
    [No Abstract]   [Full Text] [Related]  

  • 7. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
    Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
    J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
    Gadducci A; Cosio S; Lippolis PV
    Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
    Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
    J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 11. An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer.
    de Bree E; Michelakis D
    Expert Opin Pharmacother; 2020 Aug; 21(12):1479-1492. PubMed ID: 32486865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
    Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
    JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
    Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
    J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer.
    Chen WC; Huang HJ; Yang LY; Pan YB; Huang KG; Lin CT; Chen MY; Tang YH; Chang TC; Lai CH; Chou HH
    Biomed J; 2022 Oct; 45(5):821-827. PubMed ID: 34656802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intraperitoneal bevacizumab combined with hyperthermic intraperitoneal chemotherapy in the treatment of patients with ovarian cancer and peritoneal effusion and the effect on serum lncRNA H19 and VEGF levels.
    Zhang M; Bao Y; Zhang H; Li D; Mei X; Cheng X
    J Obstet Gynaecol; 2023 Dec; 43(1):2204940. PubMed ID: 37186893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
    El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
    ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
    Xia Y; Wang H; Zhang J; Wang Y
    Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developing a hyperthermic intraperitoneal chemotherapy (HIPEC) gynecologic oncology program: a Canadian experience.
    Neveu J; Tremblay E; Mercier F; Garneau S; Cormier B
    Int J Gynecol Cancer; 2023 Dec; 33(12):1957-1965. PubMed ID: 38011988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients.
    Menzies AV; Usher EC; Hsu FC; Levine EA; Lentz SS; Kelly MG
    Gynecol Oncol; 2022 Nov; 167(2):234-238. PubMed ID: 36085091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.